Media headlines about BioLife Solutions (NASDAQ:BLFS) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioLife Solutions earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 48.3727562273081 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Brokerages Expect BioLife Solutions, Inc. (BLFS) to Post ($0.07) Earnings Per Share (americanbankingnews.com)
- Stock Gaps Up Recap as of Friday – JCP, CREG, HTZ, OMER, AMDA, BLFS, FFHL (fxpips.com)
- Edited Transcript of BLFS earnings conference call or presentation 9-Nov-17 9:30pm GMT (finance.yahoo.com)
- Short Interest in BioLife Solutions, Inc. (BLFS) Expands By 44.7% (americanbankingnews.com)
- BioLife Solutions, Inc. (BLFS) Price Target Raised to $8.00 (americanbankingnews.com)
Shares of BioLife Solutions (NASDAQ BLFS) traded up $0.30 during midday trading on Tuesday, reaching $6.21. The company’s stock had a trading volume of 173,700 shares, compared to its average volume of 107,127. BioLife Solutions has a 52 week low of $1.50 and a 52 week high of $7.53.
BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, November 9th. The medical equipment provider reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. BioLife Solutions had a negative return on equity of 49.92% and a negative net margin of 52.10%. The company had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $2.60 million. equities analysts predict that BioLife Solutions will post -0.24 EPS for the current fiscal year.
Separately, Maxim Group set a $7.00 target price on BioLife Solutions and gave the stock a “buy” rating in a report on Thursday, October 19th.
TRADEMARK VIOLATION NOTICE: “BioLife Solutions (BLFS) Earns Coverage Optimism Rating of 0.15” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/14/biolife-solutions-blfs-earns-coverage-optimism-rating-of-0-15.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.